At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
neratinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
In Brief
A Phase 2 clinical trial evaluating neratinib and temsirolimus for HER2-mutant Non-Small Cell Lung Cancer. Completed, enrolled 62 participants across 21 sites in 2 countries.
Detailed Summary
This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter, multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus combination therapy in patients with non-small cell lung cancer (NSCLC) who have documented somatic HER2 mutations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2-mutant Non-Small Cell Lung Cancer
CountriesFrance, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartJul 2013
Primary CompletionSep 2016
Study CompletionOct 2017
TodayJul 2026
First PostedApr 9, 2013
Enrollment StartJul 1, 2013
Primary CompletionSep 20, 2016
Study CompletionOct 6, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 13.2 years ago
Interventions
neratinibdrug
temsirolimusdrug